CD160 antigen isoform X1 [Homo sapiens]
List of domain hits
Name | Accession | Description | Interval | E-value | |||
IgC2_CD160 | cd21392 | Immunoglobulin Constant-2 domain of Cluster of Differentiation 160 (CD160); CD160 is expressed ... |
26-144 | 3.87e-78 | |||
Immunoglobulin Constant-2 domain of Cluster of Differentiation 160 (CD160); CD160 is expressed at the cell surface as a tightly disulfide-linked multimer and is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. Structurally similar to The B and T lymphocyte attenuator (BTLA), which appears to act as a negative regulator of T cell activation and growth. CD160 is a ligand for HVEM (herpes virus entry mediator), and considered a proposed immune checkpoint inhibitor with anti-cancer activity along with anti-PD-1 antibodies. CD160 has also been proposed as a potential target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs. : Pssm-ID: 409621 Cd Length: 119 Bit Score: 230.76 E-value: 3.87e-78
|
|||||||
Name | Accession | Description | Interval | E-value | |||
IgC2_CD160 | cd21392 | Immunoglobulin Constant-2 domain of Cluster of Differentiation 160 (CD160); CD160 is expressed ... |
26-144 | 3.87e-78 | |||
Immunoglobulin Constant-2 domain of Cluster of Differentiation 160 (CD160); CD160 is expressed at the cell surface as a tightly disulfide-linked multimer and is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. Structurally similar to The B and T lymphocyte attenuator (BTLA), which appears to act as a negative regulator of T cell activation and growth. CD160 is a ligand for HVEM (herpes virus entry mediator), and considered a proposed immune checkpoint inhibitor with anti-cancer activity along with anti-PD-1 antibodies. CD160 has also been proposed as a potential target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs. Pssm-ID: 409621 Cd Length: 119 Bit Score: 230.76 E-value: 3.87e-78
|
|||||||
Name | Accession | Description | Interval | E-value | |||
IgC2_CD160 | cd21392 | Immunoglobulin Constant-2 domain of Cluster of Differentiation 160 (CD160); CD160 is expressed ... |
26-144 | 3.87e-78 | |||
Immunoglobulin Constant-2 domain of Cluster of Differentiation 160 (CD160); CD160 is expressed at the cell surface as a tightly disulfide-linked multimer and is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. Structurally similar to The B and T lymphocyte attenuator (BTLA), which appears to act as a negative regulator of T cell activation and growth. CD160 is a ligand for HVEM (herpes virus entry mediator), and considered a proposed immune checkpoint inhibitor with anti-cancer activity along with anti-PD-1 antibodies. CD160 has also been proposed as a potential target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs. Pssm-ID: 409621 Cd Length: 119 Bit Score: 230.76 E-value: 3.87e-78
|
|||||||
Blast search parameters | ||||
|